Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status

Leidinger, Petra; Hart, Martin; Backes, Christina; Rheinheimer, Stefanie; Keck, Bastian; Wullich, Bernd; Keller, Andreas; Meese, Eckart

doi:10.1007/s13277-016-4883-7

Cited by 47 publications

(34 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, miR-21 in patients’ plasma was also found as a miRNA predicting aggressiveness of prostate cancer [ 35 ]. miR-221-5p and miR-708-3p were confirmed to be downregulated in blood of prostate cancer patients compared with benign prostate hyperplasia (BPH) patients by quantitative real-time PCR (qRT-PCR) [ 36 ]. Ambs et al reported that miR-106b and miR-32 were upregulated in prostate cancer tissues [ 37 ].…”

Section: Expressions Of Mirnas In Prostate Cancer Tissuementioning

confidence: 99%

Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression

Takayama

Misawa

Inoue

2017

Cancers

View full text Add to dashboard Cite

The androgen receptor (AR) plays important roles in prostate cancer development and prostate tumor growth. After binding to androgens, AR functions as a nuclear receptor and translocates to the nucleus to bind to specific AR-binding sites (ARBSs). AR regulates epigenetic factor recruitments to activate its downstream signaling. Although androgen deprivation therapy (ADT) is initially useful for prostate cancer patients, most patients eventually show resistance with hormone-refractory prostate cancers (HRPCs) or castration-resistant prostate cancers (CRPCs). Thus, new therapeutic strategies targeting HRPCs/CRPCs should be very important for clinical medicine as well as prostate cancer biology. Past studies have shown that mechanisms such as AR overexpression, hypersensitivity, variants and reprograming are responsible for developing HRPCs/CRPCs. These findings suggest that AR target genes will be major key factors. In this review article, we focus mainly on the androgen-regulated microRNAs (miRNAs) to summarize the contribution of miRNA-mediated pathways for prostate cancer progression.

show abstract

Section: Expressions Of Mirnas In Prostate Cancer Tissuementioning

confidence: 99%

Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression

Takayama

Misawa

Inoue

2017

Cancers

View full text Add to dashboard Cite

show abstract

“…Oncogenic processes may highly influence cellular glycosylation process and PSA has carbohydrate content so it is predicted that glycosylation involves alteration of gene expression and activity of glycosyltransferases 16. One more approach of early detection of PCa using non-invasive way is to measure non-coding RNA, miRNA level in patients' blood 28. It has been shown that in PCa and BPH patients, seven miRNAs such as miR-675 levels were significantly altered in cancer and non-cancer groups 28.…”

Section: Discussionmentioning

confidence: 99%

“…One more approach of early detection of PCa using non-invasive way is to measure non-coding RNA, miRNA level in patients' blood 28. It has been shown that in PCa and BPH patients, seven miRNAs such as miR-675 levels were significantly altered in cancer and non-cancer groups 28.…”

Section: Discussionmentioning

confidence: 99%

PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis

et al. 2017

View full text Add to dashboard Cite

Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA and p2PSA4. Overall the PCa screening database is lacking in Kazakhstani patients. We analyzed the PSA levels and Gleason scores of 222 biopsies collected in 2015 in Almaty area, Kazakhstan approved by institutional ethics board. We found using PSA of 4ng/ml as threshold, only 25.68% of patients have cancer with Gleason score ranged 6-8 and 65.77% of patients have no character of cancer. Moreover, there is no significant correlation between PSA and cancerous (P=0.266) or Gleason grade (P=0.3046) based on pathological biopsy. In addition, PHI is not correlated to prostate cancer (P=0.4301). Our data suggest that false-positive rate is much higher than the correct-positive diagnosis when using PSA as the first screening. Thus in this cohort study, most patients can not get benefit from the PSA screening for precision PCa diagnosis. As Kazakhstani family trees are unique and complicated because of history and migration, the high rate of over diagnosis might be due to the hyperexpression of PSA via heterosis in Eurasian men. Therefore we should be cautious when using pro-biopsy in precision diagnosis for Eurasian prostate cancer patients.

show abstract

“…Since the benefit of prostate-specific antigen (PSA) screening remains controversial, new non-invasive biomarkers for prostate carcinoma (PCa) are still required, new evidence showed that microRNAs (miRNAs) in whole peripheral blood can separate patients with localized prostate cancer from healthy individuals [15].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Prostate Cancer with Highest Reported PSA Level

Martha

Tilincă

Tătaru

et al. 2016

Acta Medica Marisiensis

View full text Add to dashboard Cite

Introduction: Prostate cancer is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe. Metastatic prostate cancer among young patients represents the rarest of the newly diagnosed prostate cancer, with few reports of cases with a longer survival. Case presentation: We present the case of a 59 year-old male who was referred with back pain over the last month. Digital rectal examination highlighted an enlarged and totally indurated prostate of 4x4.5 cm, while abdominopelvic X-rays showed osteoblastic metastases in the spine and pelvis bones. Laboratory examinations revealed a Prostate Specific Antigen level of 7941 ng/ml. Prostate biopsy histology showed a bilateral prostate cancer with a Gleason score of 8. Androgen deprivation therapy and daily administration of biphosphonates were prescribed. After two years of treatment, the Prostate Specific Antigen level decreases to 8 ng/ml. Conclusions: We reported the highest Prostate Specific Antigen level in a patient under 60 years old with metastatic prostate cancer. Prostate cancer remains an important public health problem due to the aggressiveness of the disease and advanced stage upon diagnosis. Prostate Specific Antigen is mandatory to evaluate, to have a reference level in order to prevent metastatic prostate cancer in young patients at diagnosis. IntroductionProstate cancer (PCa) is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe, North America, and parts of Africa [1]. In 2000, there were 513,000 newly diagnosed cases worldwide, while in 2012 there were 1.1 million. This suggests an increased incidence of prostate cancer in the past decade [2].Prostate-specific antigen (PSA) is a protein produced by the epithelial cells of the prostate gland. Its main attribution is to liquefy the semen in the seminal coagulum allowing the sperm to move freely. PSA is present in the serum in small quantities in healthy people, but it has an elevated level in case of prostate cancer or other prostatic disorders.Even if PCa is an important health problem worldwide, screening based on Prostate-Specific Antigen (PSA) determination seems to increase the overall health care costs and early detection of prostate cancer, leading to an earlier treatment with several years before regular occurrence. Decision analysis models have been used to evaluate the effectiveness of prostate cancer screening and treatment, but little or no benefit was found [3].Metastatic Pca (mPCa) among young patients represents few of the newly diagnosed PCa, most of the clinical trials showed a mean survival after diagnosis up to 3 years, with few case reports of longer survival [4]. Very high PSA levels in mPCa at diagnosis are rarely reported and none referring to a Caucasian male under 60 years old [5,6]. Case presentationWe present the case of a 59 year-old Caucasian male patient who was referred to the Urology Emergency Unit of the Mures County Hospital...

show abstract

Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status

Cited by 47 publications

References 49 publications

Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression

Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression

PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis

Metastatic Prostate Cancer with Highest Reported PSA Level

Contact Info

Product

Resources

About